Acteoside

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Acteoside
Accession Number
DB12996
Type
Small Molecule
Groups
Investigational
Description

Acteoside is under investigation in clinical trial NCT02662283 (Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy).

Structure
Thumb
Synonyms
Not Available
External IDs
TJC-160
Categories
UNII
3TGX09BD5B
CAS number
61276-17-3
Weight
Average: 624.5871
Monoisotopic: 624.205420482
Chemical Formula
C29H36O15
InChI Key
FBSKJMQYURKNSU-ZLSOWSIRSA-N
InChI
InChI=1S/C29H36O15/c1-13-22(36)23(37)24(38)29(41-13)44-27-25(39)28(40-9-8-15-3-6-17(32)19(34)11-15)42-20(12-30)26(27)43-21(35)7-4-14-2-5-16(31)18(33)10-14/h2-7,10-11,13,20,22-34,36-39H,8-9,12H2,1H3/b7-4+/t13-,20+,22-,23+,24+,25+,26+,27+,28+,29-/m0/s1
IUPAC Name
(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-(hydroxymethyl)-4-{[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-3-yl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
SMILES
C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCC3=CC(O)=C(O)C=C3)O[C@H](CO)[C@H]2OC(=O)\C=C\C2=CC(O)=C(O)C=C2)[C@H](O)[C@H](O)[C@H]1O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Acteoside.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Acteoside.Experimental
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Acteoside.Approved, Investigational, Withdrawn
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Acteoside is combined with Anthrax immune globulin human.Approved
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Acteoside is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Acteoside is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Acteoside.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Acteoside.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Acteoside.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Acteoside is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Acteoside is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Acteoside.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Acteoside.Experimental
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Acteoside.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Acteoside.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Acteoside.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Acteoside.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Acteoside.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Acteoside.Approved, Investigational
FingolimodActeoside may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Acteoside is combined with G17DT.Investigational
GI-5005The risk or severity of adverse effects can be increased when Acteoside is combined with GI-5005.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Acteoside.Experimental
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Acteoside is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Acteoside is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Acteoside is combined with Human rabies virus immune globulin.Approved
INGN 201The risk or severity of adverse effects can be increased when Acteoside is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Acteoside is combined with INGN 225.Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Acteoside is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Acteoside.Experimental
LeflunomideThe risk or severity of adverse effects can be increased when Acteoside is combined with Leflunomide.Approved, Investigational
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Acteoside.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Acteoside is combined with Natalizumab.Approved, Investigational
OcrelizumabOcrelizumab may increase the immunosuppressive activities of Acteoside.Approved, Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Acteoside.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Acteoside.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Acteoside.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Acteoside.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Acteoside.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Acteoside.Experimental
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Acteoside is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Acteoside.Approved, Investigational
RindopepimutThe risk or severity of adverse effects can be increased when Acteoside is combined with Rindopepimut.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Acteoside.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Acteoside is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Acteoside is combined with Rubella virus vaccine.Approved, Investigational
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Acteoside is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Acteoside is combined with Salmonella typhi ty21a live antigen.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Acteoside.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Acteoside is combined with SRP 299.Investigational
TacrolimusTacrolimus may increase the immunosuppressive activities of Acteoside.Approved, Investigational
TecemotideThe risk or severity of adverse effects can be increased when Acteoside is combined with Tecemotide.Investigational
Technetium Tc-99m oxidronateActeoside can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TG4010The risk or severity of adverse effects can be increased when Acteoside is combined with TG4010.Investigational
TofacitinibActeoside may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Acteoside.Approved, Investigational
Typhoid VaccineThe risk or severity of adverse effects can be increased when Acteoside is combined with Typhoid Vaccine.Approved
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Acteoside is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Acteoside is combined with Yellow Fever Vaccine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C10501
PubChem Compound
5281800
PubChem Substance
347829133
ChemSpider
4445112
BindingDB
50241867
ChEBI
132853
ChEMBL
CHEMBL444478
Wikipedia
Verbascoside

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.966 mg/mLALOGPS
logP1.09ALOGPS
logP0.82ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)9.01ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count14ChemAxon
Hydrogen Donor Count9ChemAxon
Polar Surface Area245.29 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity148.4 m3·mol-1ChemAxon
Polarizability60.62 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as coumaric acids and derivatives. These are aromatic compounds containing Aromatic compounds containing a cinnamic acid moiety (or a derivative thereof) hydroxylated at the C2 (ortho-), C3 (meta-), or C4 (para-) carbon atom of the benzene ring.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Cinnamic acids and derivatives
Sub Class
Hydroxycinnamic acids and derivatives
Direct Parent
Coumaric acids and derivatives
Alternative Parents
Cinnamic acid esters / O-glycosyl compounds / Disaccharides / Tyrosols and derivatives / Styrenes / Catechols / 1-hydroxy-2-unsubstituted benzenoids / 1-hydroxy-4-unsubstituted benzenoids / Fatty acid esters / Oxanes
show 10 more
Substituents
Coumaric acid or derivatives / Cinnamic acid ester / Disaccharide / Glycosyl compound / O-glycosyl compound / Tyrosol derivative / Catechol / Styrene / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid
show 24 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
hydroxycinnamic acid (CHEBI:9953)

Drug created on October 20, 2016 19:53 / Updated on July 02, 2018 19:44